Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new era for polycythemia vera treatment has arrived. Rusfertide (Mimrylo), a first-in-class hepcidin mimetic, received FDA approval in August 2026 and is now a Category 1 NCCN recommendation for both low- and high-risk PV. Phase 3 VERIFY trial data show 77% of patients achieved clinical response vs. 33% on placebo, with dramatically fewer phlebotomies needed.
Polycythemia vera (PV) patients have long been stuck in a frustrating cycle: too many red blood cells, repeated phlebotomies to control hematocrit, and worsening iron deficiency that perpetuates the problem. Rusfertide (Mimrylo), a first-in-class hepcidin mimetic developed by Takeda, is now changing that equation. The FDA approved it in August 2026, and updated NCCN guidelines have since designated it a Category 1 treatment option across both low- and high-risk PV — the only therapy to hold that distinction across both risk groups.
The phase 3 VERIFY trial (n = 293) underpinning the approval showed rusfertide, added to standard of care, dramatically outperformed placebo in controlling hematocrit and reducing phlebotomy burden. Patients self-administer the once-weekly subcutaneous injection, offering independence from frequent clinic visits. The most common side effects were injection site reactions, anemia, and fatigue — generally mild and manageable.
By the Numbers:
Why it matters: PV is a lifelong condition with a median survival of 15–20 years, making quality of life paramount. Rusfertide not only controls hematocrit more consistently than phlebotomy but also significantly improves patient-reported fatigue and quality of life — addressing what patients say matters most.
